Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
The company expects to launch this product through its marketing partner in the near future
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
There are 38.4 million people with diabetes in the United States
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Subscribe To Our Newsletter & Stay Updated
